CEO David Lazar expands Quantum Cyber N.V. (NASDAQ: MYNZ) preferred stake

Rhea-AI Filing Summary

Quantum Cyber N.V. Chief Executive Officer David E. Lazar reported new preferred share holdings and no beneficial ownership of ordinary shares. As of April 22, 2026, he beneficially owns 0 ordinary shares.

On that date, he was granted 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares at $1.50 per share, for an additional purchase price of $3,000,000. These Second Closing Shares follow a prior purchase of 1,000,000 Series A, 1,000,000 Series B, and 1,000,000 Series C Preferred Shares at $1.00 per share, totaling $3,000,000.

After stockholder approval on April 22, 2026, each First Closing Share is convertible into 9 ordinary shares and each Second Closing Share is convertible into 225 ordinary shares at the reporting person’s option for no additional consideration. Stockholders also approved increasing authorized ordinary shares to at least 900,000,000, a reverse stock split, conversion of all Preferred Shares into ordinary shares in compliance with Nasdaq rules, and election of Lazar and his designees to the board. Each class of Preferred Stock is perpetual with no expiration date.

Insights

Equity structure & governance analyst

CEO David Lazar expanded preferred holdings that can convert into large ordinary share stakes.

The filing shows David E. Lazar, CEO and 10% owner of Quantum Cyber N.V., acquiring 1,000,000 Series D and 1,000,000 Series E Preferred Shares at $1.50 each, adding to earlier preferred purchases totaling $3,000,000. All classes are now convertible into ordinary shares after stockholder approval.

That approval also increased authorized ordinary shares to at least 900,000,000, enabled conversion of all Preferred Shares into ordinary shares consistent with Nasdaq rules, approved a reverse stock split, and elected Lazar and his designees to the board. These steps collectively reshape capital structure and governance, concentrating significant potential equity exposure with the CEO while ordinary share ownership is reported as zero in this filing.

Future company disclosures can clarify how and when Lazar chooses to convert Preferred Shares into ordinary shares, and how the reverse stock split and expanded authorization interact with existing and potential future issuances.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Lazar David E.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Series D Preferred Shares	1,000,000	$1.50	$1.50M
Grant/Award	Series E Preferred Shares	1,000,000	$1.50	$1.50M
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Series D Preferred Shares — 1,000,000 shares (Direct, null); Series E Preferred Shares — 1,000,000 shares (Direct, null); Ordinary Shares — 0 shares (Direct, null)

Footnotes (1)

1. No ordinary shares are beneficially owned. As previously reported, on February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Following Stockholder Approval (as defined below) which was obtained on April 22, 2026, the Reporting Person subsequently acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. On April 22, 2026, the Company's shareholdes approved (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following the receipt of Stockholder Approval, each of the First Closing Shares are now convertible into 9 ordinary shares and each of the Second Closing Shares are now convertible into 225 ordinary shares. The Preferred Stock are convertible into ordinary shares at the option of the Reporting Person for no additional consideration. Each class of Preferred Stock is perpetual and therefore has no expiration date.

Key Figures

Series D Preferred Shares granted: 1,000,000 shares Series E Preferred Shares granted: 1,000,000 shares Second Closing purchase price: $1.50 per share +5 more

8 metrics

Series D Preferred Shares granted 1,000,000 shares Grant to David E. Lazar on April 22, 2026

Series E Preferred Shares granted 1,000,000 shares Grant to David E. Lazar on April 22, 2026

Second Closing purchase price $1.50 per share Price for Series D and E Preferred Shares

Second Closing aggregate price $3,000,000 Total paid for Series D and E Preferred Shares

First Closing aggregate price $3,000,000 Total for Series A, B, C Preferred Shares at $1.00

First Closing conversion ratio 9 ordinary shares per Preferred Share Series A, B, C conversion terms after approval

Second Closing conversion ratio 225 ordinary shares per Preferred Share Series D and E conversion terms after approval

Authorized ordinary shares at least 900,000,000 New authorization approved April 22, 2026

Key Terms

Series E Preferred Shares, Series D Preferred Shares, Preferred Shares, Stockholder Approval, +2 more

6 terms

Series E Preferred Shares financial

"the Reporting Person subsequently acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares"

Series E preferred shares are a specific class of stock issued later in a company’s fundraising that gives holders priority over common shareholders for dividend payments and claims on assets. Think of them as a later-issued “front-of-line” ticket that often includes rights to convert into common stock and to receive money before common holders in a sale or bankruptcy, so their presence affects potential payouts, ownership dilution, and control for all investors.

Series D Preferred Shares financial

"the Reporting Person subsequently acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares"

Preferred Shares financial

"collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares""

Preferred shares are a type of investment that gives investors priority over common shareholders when it comes to receiving dividends and getting their money back if a company is sold or liquidated. Think of them as a safer, more predictable way to earn income from a company's profits, similar to a fixed-return investment, but without voting rights. This makes preferred shares appealing to those seeking stable income with a higher claim on assets than regular stockholders.

Stockholder Approval regulatory

"collectively, the "Stockholder Approval""

Stockholder approval is formal consent given by a company’s shareholders, usually through a vote at a meeting or by proxy, for major actions such as mergers, asset sales, changes to corporate structure, or amendments to governance rules. Investors pay attention because the vote can enable or block steps that materially change a company’s direction, ownership or value—like neighbors voting to allow a major renovation that would alter a building’s use and worth.

reverse stock split financial

"approved (a) an increase ... (c) a reverse stock split, and (d) the election"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

authorized ordinary shares financial

"approved (a) an increase in the Company's authorized ordinary shares to at least 900,000,000"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lazar David E.

(Last) (First) (Middle)

44, TOWER 100, THE TOWERS

WINSTON CHURCHILL, PAITILLA

(Street)

PANAMA CITY PANAMA 07196

(City) (State) (Zip)

PANAMA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Quantum Cyber N.V. [ MYNZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								0(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series D Preferred Shares(2)(3)	(4)	04/22/2026		A		1,000,000		04/22/2026(3)	(5)	Ordinary Shares	225,000,000	$1.5(2)	1,000,000	D
Series E Preferred Shares(2)(3)	(4)	04/22/2026		A		1,000,000		04/22/2026(3)	(5)	Ordinary Shares	225,000,000	$1.5(2)	1,000,000	D

Explanation of Responses:

1. No ordinary shares are beneficially owned.

2. As previously reported, on February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Following Stockholder Approval (as defined below) which was obtained on April 22, 2026, the Reporting Person subsequently acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000.

3. On April 22, 2026, the Company's shareholdes approved (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following the receipt of Stockholder Approval, each of the First Closing Shares are now convertible into 9 ordinary shares and each of the Second Closing Shares are now convertible into 225 ordinary shares.

4. The Preferred Stock are convertible into ordinary shares at the option of the Reporting Person for no additional consideration.

5. Each class of Preferred Stock is perpetual and therefore has no expiration date.

	/s/ David E. Lazar	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Quantum Cyber N.V. (MYNZ) report for David E. Lazar?

The filing shows David E. Lazar received 1,000,000 Series D and 1,000,000 Series E Preferred Shares at $1.50 per share. These derivative grants follow earlier purchases of Series A, B, and C Preferred Shares and give him significant potential ordinary share exposure through conversion rights.

How much has David E. Lazar invested in Quantum Cyber N.V. preferred shares?

Footnotes state Lazar first bought 1,000,000 Series A, 1,000,000 Series B, and 1,000,000 Series C Preferred Shares at $1.00 each for $3,000,000. After stockholder approval, he acquired 1,000,000 Series D and 1,000,000 Series E at $1.50 each for another $3,000,000.

What are the conversion terms of Quantum Cyber N.V.’s Preferred Shares held by Lazar?

Following stockholder approval on April 22, 2026, each Series A, B, and C Preferred Share is convertible into 9 ordinary shares. Each Series D and E Preferred Share is convertible into 225 ordinary shares. Conversions are at Lazar’s option for no additional consideration, subject to the approved structure.

Does David E. Lazar own any Quantum Cyber N.V. ordinary shares after this Form 4?

A footnote states that no ordinary shares are beneficially owned. The filing shows zero ordinary shares following the reported transactions, while Lazar holds multiple classes of Preferred Shares that are now convertible into ordinary shares under the approved terms.

What corporate actions did Quantum Cyber N.V. stockholders approve on April 22, 2026?

Stockholders approved increasing authorized ordinary shares to at least 900,000,000, converting all Preferred Shares into ordinary shares in line with Nasdaq rules, implementing a reverse stock split, and electing David E. Lazar and his designees to the board, collectively termed the Stockholder Approval.

Do Quantum Cyber N.V.’s Preferred Shares held by Lazar have an expiration date?

The filing notes each class of Preferred Stock is perpetual and therefore has no expiration date. This means Lazar’s conversion rights into ordinary shares remain outstanding indefinitely, subject to the approved capital structure and applicable market rules.